A Phase 3 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Terminated at 81 sites in 21 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.
Among the 12 studies testing lebrikizumab in Asthma, this one is the 3rd largest by enrollment, is one of 3 that started in 2013, is one of 5 in phase 3, and was the 8th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2013.
This study's enrollment of 346 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 224 across the 12 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
41 studies in Asthma by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 39 finished, 16 (41%) have results posted.
Among the 41 studies in Asthma by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2013, is one of 9 in phase 3, and was the 29th registered.
Hoffmann-La Roche’s Asthma studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing lebrikizumab in Asthma, from their registry updates:
Among Hoffmann-La Roche’s 41 in Asthma:
This tab as a report to print or save as PDF → With an account.
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy, safety, and tolerability of lebrikizumab in adolescent participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroids (ICS) therapy and at least one second controller medication. Participants will be randomized in a 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ('High' or 'Low') or placebo, administered as subcutaneous (SC) every 4 weeks (Q4W) for 52 weeks, in addition to their standard-of-care therapy. This will be followed by an optional 52-week double-blind active-treatment extension. The anticipated time on study treatment is up to 104 weeks. Participants who complete the study to Week 104, discontinue prematurely or decide not to take part in the optional active-treatment extension will transition to the 20-week safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms \[mcg\] of fluticasone propionate dry powder inhaler \[DPI\] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
Drug: Lebrikizumab · Drug: Standard of Care
Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
Drug: Lebrikizumab · Drug: Standard of Care
Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
Drug: Lebrikizumab · Drug: Placebo · Drug: Standard of Care
Lebrikizumab will be administered as SC injection at high or low dose Q4W.
Lebrikizumab matching placebo will be administered as SC injection Q4W.
Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period
An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.
Time frame: Baseline up to Week 52
Percent Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. The percentage change in pre-bronchodilator FEV1 was defined as the change in FEV1 (in liters) from baseline divided by the FEV1 (in liters) at baseline multiplied by 100.
Time frame: Week 52
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.
Time frame: Week 52
Time to First Asthma Exacerbation
An asthma exacerbation was defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids was defined as treatment with oral, IV, or IM corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Median time to first protocol-defined asthma exacerbation was estimated using Kaplan-Meier analysis. 95% Confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
Time frame: Baseline up to Week 52
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 52
Measurement of FeNO (in parts per billion \[ppb\]) was performed using a hand-held portable NIOX MINO® device, in accordance with guidelines published by the American Thoracic Society (ATS) and described in the pulmonary function testing manual.
Time frame: Week 52
Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Overall Score at Week 52
The Standardized AQLQ+12 was used to assess the participants' asthma-specific health-related quality of life. The AQLQ+12 had a recall specification of 2 weeks. The AQLQ+12 was a 32-item questionnaire with 4 domains: activity limitations, symptoms, emotional function, and environmental stimuli. Each of the 32 questions were scored on a scale 1-7. The overall AQLQ+12 score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7 indicated no impairments due to asthma, and a score of 1 indicated severe impairment.
Time frame: Week 52
Change From Baseline in Asthma Rescue Medication Use at Week 52
Participants were allowed to use short-acting bronchodilators as asthma rescue medication. Baseline asthma rescue medication use was defined as the average number of puffs per day over the 7 days prior to and on the day of randomization. Participants must have recorded their asthma rescue medication use for at least 4 days to have a baseline score calculated. The post-baseline asthma medication use for any timepoint was defined as the average number of puffs per day over the last 28 days on or prior to the timepoint. Participants must have recorded their asthma rescue medication use for at least 14 days during a 28-day interval to have a score calculated for the respective timepoint. For nebulizer use, one treatment (inhalation) was considered equivalent to 4 puffs.
Time frame: Week 52
Rate of Urgent Asthma-Related Health Care Utilization (HCU) Events
Urgent asthma-related HCU events included hospitalizations, emergency department visits, and acute care visits. Rate of urgent asthma-related HCU events = total number of urgent asthma-related HCU events divided by total follow-up time in patient years.
Time frame: Baseline up to Week 52
Injection Acceptability Questionnaire (IAQ) Score
The acceptability of the injections of study drug was addressed by measuring the level of pain that participants experienced. Participants assessed pain associated with study drug administration using the IAQ within 10 minutes of study drug administration. The IAQ score ranged from 0 to 10; where 0 = no pain and 10 = worst pain imaginable.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48
Minimum Observed Serum Concentration (Ctrough) for Lebrikizumab
Participants who received at least one dose of lebrikizumab and had at least one post-baseline evaluable sample were included in the analysis. Results of post-dose samples which were less than reportable were set to 0.045 micrograms per milliliter (mcg/mL) that is half of minimum quantifiable concentration value (0.09 mcg/mL).
Time frame: Predose (Hour 0) at Weeks 4, 12, 24, 36, and 52
| Milestone | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Placebo/Lebrikizumab 37.5 mg | Placebo/Lebrikizumab 125 mg |
|---|---|---|---|---|---|
| Started | 56 | 113 | 116 | 30 | 31 |
| Completed | 0 | 30 | 31 | 16 | 14 |
| Not completed | 56 | 83 | 85 | 14 | 17 |
| Withdrew: Study terminated by sponsor | 35 | 61 | 66 | 9 | 13 |
| Withdrew: Withdrawal by subject | 16 | 13 | 5 | 4 | 1 |
| Withdrew: Lost to follow-up | 4 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Missing | 0 | 4 | 9 | 1 | 2 |
| Withdrew: Other | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 1 |
An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.
| events per patient year | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period | 0.43 | 0.26 | 0.21 |
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. The percentage change in pre-bronchodilator FEV1 was defined as the change in FEV1 (in liters) from baseline divided by the FEV1 (in liters) at baseline multiplied by 100.
| percent change | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Percent Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | 19 ± 3 | 25 ± 3 | 20 ± 3 |
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.
| millilitre (mL) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52 | 370 ± 54 | 568 ± 53 | 423 ± 54 |
An asthma exacerbation was defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids was defined as treatment with oral, IV, or IM corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Median time to first protocol-defined asthma exacerbation was estimated using Kaplan-Meier analysis. 95% Confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.
| weeks | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Time to First Asthma Exacerbation | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Measurement of FeNO (in parts per billion \[ppb\]) was performed using a hand-held portable NIOX MINO® device, in accordance with guidelines published by the American Thoracic Society (ATS) and described in the pulmonary function testing manual.
| ppb | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 52 | 3.93 ± 2.81 | -18.05 ± 2.70 | -26.40 ± 2.76 |
The Standardized AQLQ+12 was used to assess the participants' asthma-specific health-related quality of life. The AQLQ+12 had a recall specification of 2 weeks. The AQLQ+12 was a 32-item questionnaire with 4 domains: activity limitations, symptoms, emotional function, and environmental stimuli. Each of the 32 questions were scored on a scale 1-7. The overall AQLQ+12 score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7 indicated no impairments due to asthma, and a score of 1 indicated severe impairment.
| units on a scale | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Overall Score at Week 52 | 1.05 ± 0.11 | 1.17 ± 0.11 | 1.21 ± 0.11 |
Participants were allowed to use short-acting bronchodilators as asthma rescue medication. Baseline asthma rescue medication use was defined as the average number of puffs per day over the 7 days prior to and on the day of randomization. Participants must have recorded their asthma rescue medication use for at least 4 days to have a baseline score calculated. The post-baseline asthma medication use for any timepoint was defined as the average number of puffs per day over the last 28 days on or prior to the timepoint. Participants must have recorded their asthma rescue medication use for at least 14 days during a 28-day interval to have a score calculated for the respective timepoint. For nebulizer use, one treatment (inhalation) was considered equivalent to 4 puffs.
| puffs per day | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Change From Baseline in Asthma Rescue Medication Use at Week 52 | -0.64 ± 0.24 | -0.68 ± 0.24 | -0.50 ± 0.23 |
Urgent asthma-related HCU events included hospitalizations, emergency department visits, and acute care visits. Rate of urgent asthma-related HCU events = total number of urgent asthma-related HCU events divided by total follow-up time in patient years.
| events per patient year | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Rate of Urgent Asthma-Related Health Care Utilization (HCU) Events | 0.21 | 0.08 | 0.06 |
The acceptability of the injections of study drug was addressed by measuring the level of pain that participants experienced. Participants assessed pain associated with study drug administration using the IAQ within 10 minutes of study drug administration. The IAQ score ranged from 0 to 10; where 0 = no pain and 10 = worst pain imaginable.
| units on a scale | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|---|
| Baseline (n= 107, 100, 105) | 3.5 ± 2.6 | 3.5 ± 2.3 | 3.9 ± 2.6 |
| Week 4 (n= 101, 102, 105) | 3.7 ± 2.7 | 4.1 ± 2.6 | 3.9 ± 2.7 |
| Week 8 (n= 91, 95, 102) | 3.7 ± 2.5 | 3.7 ± 2.4 | 3.5 ± 2.4 |
| Week 12 (n= 92, 92, 96) | 3.4 ± 2.4 | 3.4 ± 2.7 | 3.5 ± 2.5 |
| Week 16 (n= 87, 88, 95) | 3.2 ± 2.5 | 3.2 ± 2.6 | 3.3 ± 2.5 |
| Week 20 (n= 84, 84, 87) | 3.1 ± 2.4 | 3.0 ± 2.6 | 3.1 ± 2.4 |
| Week 24 (n= 80, 82, 85) | 3.3 ± 2.3 | 3.1 ± 2.5 | 3.3 ± 2.1 |
| Week 28 (n= 82, 81, 84) | 2.9 ± 2.2 | 2.8 ± 2.4 | 2.8 ± 2.2 |
| Week 32 (n= 83, 79, 80) | 2.9 ± 2.2 | 2.9 ± 2.7 | 3.0 ± 2.1 |
| Week 36 (n= 77, 73, 80) | 3.1 ± 2.3 | 3.1 ± 2.7 | 3.1 ± 2.1 |
| Week 40 (n= 70, 69, 74) | 3.0 ± 2.3 | 3.0 ± 2.4 | 2.7 ± 2.1 |
| Week 44 (n= 58, 65, 73) | 2.9 ± 2.1 | 2.9 ± 2.2 | 3.2 ± 2.4 |
| Week 48 (n= 58, 60, 67) | 2.9 ± 2.3 | 2.9 ± 2.6 | 2.7 ± 2.2 |
Participants who received at least one dose of lebrikizumab and had at least one post-baseline evaluable sample were included in the analysis. Results of post-dose samples which were less than reportable were set to 0.045 micrograms per milliliter (mcg/mL) that is half of minimum quantifiable concentration value (0.09 mcg/mL).
| mcg/mL | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg |
|---|---|---|
| Week 4 (n= 47, 50) | 3.25 ± 1.58 | 12.2 ± 5.28 |
| Week 12 (n=42, 40) | 5.72 ± 2.81 | 21.7 ± 9.37 |
| Week 24 (n= 28, 29) | 7.15 ± 6.23 | 25.7 ± 9.84 |
| Week 36 (n= 18, 23) | 3.88 ± 2.92 | 23.9 ± 9.87 |
| Week 52 (n= 4, 0) | NA ± NA | — |
Collected over Baseline up to 24 weeks after last dose of study treatment (overall 124 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/56 (0%) | 3/56 (5.4%) | 23/56 (41.1%) |
| Lebrikizumab 37.5 mg | 0/113 (0%) | 6/113 (5.3%) | 67/113 (59.3%) |
| Lebrikizumab 125 mg | 0/116 (0%) | 8/116 (6.9%) | 72/116 (62.1%) |
| Placebo/ Lebrikizumab 37.5 mg | 0/30 (0%) | 3/30 (10%) | 23/30 (76.7%) |
| Placebo/ Lebrikizumab 125 mg | 0/31 (0%) | 4/31 (12.9%) | 24/31 (77.4%) |
| Event | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Placebo/ Lebrikizumab 37.5 mg | Placebo/ Lebrikizumab 125 mg |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/56 | 2/113 | 2/116 | 1/30 | 2/31 |
| SinusitisInfections and infestations | 0/56 | 0/113 | 0/116 | 1/30 | 0/31 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 0/56 | 0/113 | 0/116 | 1/30 | 0/31 |
| HeadacheNervous system disorders | 0/56 | 0/113 | 0/116 | 1/30 | 0/31 |
| Abdominal painGastrointestinal disorders | 0/56 | 0/113 | 0/116 | 0/30 | 1/31 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/56 | 0/113 | 0/116 | 0/30 | 1/31 |
| DiarrhoeaGastrointestinal disorders | 1/56 | 0/113 | 0/116 | 0/30 | 0/31 |
| VomitingGastrointestinal disorders | 1/56 | 0/113 | 0/116 | 0/30 | 0/31 |
| DehydrationMetabolism and nutrition disorders | 1/56 | 0/113 | 1/116 | 0/30 | 0/31 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/56 | 0/113 | 0/116 | 0/30 | 0/31 |
| Event | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Placebo/ Lebrikizumab 37.5 mg | Placebo/ Lebrikizumab 125 mg |
|---|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 12/56 | 25/113 | 31/116 | 11/30 | 15/31 |
| PharyngitisInfections and infestations | 5/56 | 10/113 | 18/116 | 8/30 | 4/31 |
| NasopharyngitisInfections and infestations | 4/56 | 14/113 | 13/116 | 6/30 | 7/31 |
| HeadacheNervous system disorders | 2/56 | 8/113 | 11/116 | 3/30 | 6/31 |
| Upper respiratory tract infectionInfections and infestations | 3/56 | 16/113 | 11/116 | 2/30 | 2/31 |
| BronchitisInfections and infestations | 2/56 | 10/113 | 6/116 | 4/30 | 4/31 |
| GastroenteritisInfections and infestations | 1/56 | 3/113 | 3/116 | 3/30 | 1/31 |
| RhinitisInfections and infestations | 1/56 | 5/113 | 6/116 | 3/30 | 3/31 |
| Acute sinusitisInfections and infestations | 0/56 | 2/113 | 3/116 | 1/30 | 3/31 |
| TonsillitisInfections and infestations | 2/56 | 9/113 | 8/116 | 2/30 | 3/31 |
The intent-to-treat (ITT) population included all randomized participants who received at least one dose of study medication or have any post-baseline efficacy data.
| Age, Continuous(years) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Total |
|---|---|---|---|---|
| Mean | 14.1 ± 1.7 | 14.2 ± 1.5 | 14.2 ± 1.6 | 14.2 ± 1.6 |
| Sex: Female, Male(Participants) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Total |
|---|---|---|---|---|
| Female | 49 | 43 | 59 | 151 |
| Male | 68 | 70 | 57 | 195 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 39 | 42 | 33 | 114 |
| Not Hispanic or Latino | 77 | 71 | 81 | 229 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 1 | 5 |
| Asian | 3 | 3 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 9 | 13 | 13 | 35 |
| White | 84 | 75 | 74 | 233 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 18 | 20 | 24 | 62 |
| Age group (years)(Participants) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Total |
|---|---|---|---|---|
| 12 to 14 | 71 | 64 | 67 | 202 |
| 15 to 17 | 46 | 49 | 49 | 144 |
| Baseline Use of Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA)(Participants) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Total |
|---|---|---|---|---|
| ICS < 1000 µg/day or no LABA | 87 | 88 | 88 | 263 |
| ICS >= 1000 µg/day and LABA | 30 | 25 | 28 | 83 |
| Number of Asthma Exacerbations in Last 12 Months(Asthma Exacerbations) | Placebo | Lebrikizumab 37.5 mg | Lebrikizumab 125 mg | Total |
|---|---|---|---|---|
| Mean | 1.6 ± 2.1 | 1.4 ± 1.9 | 1.7 ± 1.9 | 1.6 ± 1.9 |
Ran from Aug 2013 to primary completion in Dec 2016, 40 months.
Results were first posted in Jun 2026, 9 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab